GlassScriptPhysician profile
Sabrina Raja
NPI 1164456083
$1,890.66
in general payments reported to CMS, 2019-2025
23 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.56 · 2022: $501 · 2023: $410 · 2024: $401 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.46 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.51 | 2022-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $179.93 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $167.37 | 2022-2025 | Entyvio |
| Qol Medical, LLC | $100.52 | 2022-2025 | Sucraid |
| Gilead Sciences, INC. | $94.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $67.70 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $44.75 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $41.85 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $38.66 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $35.58 | 2022-2024 | Dificid |
| Celgene Corporation | $35.33 | 2022-2023 | Zeposia |
| Daiichi Sankyo INC. | $35.17 | 2022-2024 | Injectafer |
| Genzyme Corporation | $34.76 | 2022-2023 | |
| Pfizer INC. | $33.64 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $29.86 | 2023 | Linzess |
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Biocon Biologics INC | $21.99 | 2025 | Yesintek |
| Intercept Pharmaceuticals, INC. | $21.21 | 2024 | |
| Redhill Biopharma INC. | $16.56 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.59 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $14.49 | 2025 | Zenpep |
| Amgen INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.